Ipamorelin vs CJC-1295

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

Ipamorelin: DCJC-1295: D

Attribute	Ipamorelin	CJC-1295
Category	Growth Hormone Secretagogue	Growth Hormone Secretagogue
Evidence Rating	D — Preclinical	D — Preclinical
Clinical Status	Research-only / Not approved for human use	Research-only / Not approved for human use
Mechanism	Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. Its structural specificity means it fits only the GH...	CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. The released IGF-1 travels to muscle tissue fo...
Half-Life	~2 hours	No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days
Bioavailability	High SC bioavailability	—
Molecular Weight	~711.9 g/mol	No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol
WADA Status	Prohibited	Prohibited
Dosing	100–300 mcg per injection, 2–3x daily, 2–3 times daily (typically before meals and before bed) (Subcutaneous)	No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly, Once daily (no DAC) or 2–3 times weekly (with DAC) (Subcutaneous)
Key Use Cases	Anti-Aging Body Composition Sleep	Anti-Aging Body Composition
Safety Concerns	Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation	Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Contraindications	Active malignancy or personal/family history of cancer (GH promotes cell proliferation) Pregnancy and breastfeeding Pituitary disorders or prior pituitary surgery Diabetes with retinopathy (GH can affect blood glucose and worsen retinopathy)	Active malignancy or history of cancer (GH promotes cell proliferation) Pregnancy and breastfeeding Pituitary tumors or prior pituitary surgery Diabetes or pre-diabetes (risk of insulin resistance from sustained GH elevation)
Regulatory (US)	Not FDA-approved. Research chemical only. WADA-banned (S2 growth factor).	Not FDA-approved. Research chemical only. WADA-banned under Section S2 (growth factors and related substances).

Shop Ipamorelin

View Ipamorelin Product

Shop CJC-1295

View CJC-1295 Product

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All Comparisons Browse Catalog

Ipamorelin vs CJC-1295

Explore MoreComparisons

Your Cart

Explore More
Comparisons